Ke Xu

Diagnostic and prognostic values of serum insulin‐like growth factor binding protein 4 expression in cervical cancer

Abstract Objective Insulin‐like growth factor binding protein 4 (IGFBP4) is lowly expressed in cervical cancer (CC) cells. However, it remains unclear about its expression and diagnostic and prognostic values in CC. Therefore, this research probed the serum expression of IGFBP4 in CC patients and its diagnostic and prognostic values. Methods This study prospectively included 146 CC patients admitted to our hospital (the CC group) from January 2018 to June 2020 and 146 patients with cervical intraepithelial neoplasia (CIN) admitted to the hospital (the CIN group) and 146 normal women receiving health checkups during the same period (the normal group). Serum IGFBP4 expression in CC patients was detected with quantitative reverse transcription‐polymerase chain reaction. Receiver‐operating characteristic (ROC) curves were utilized to evaluate whether serum IGFBP4 expression could assist in predicting CC occurrence. Kaplan–Meier survival analysis and Cox regression analysis were utilized to assess the significance of serum IGFBP4 expression in the prognosis of CC patients. Results IGFBP4 was downregulated in serum from CIN and CC patients, with lower expression in CC patients. Marked differences were noted in histologic differentiation, FIGO stage, and lymph node metastasis between the high and low IGFBP4 expression groups. The area under the ROC curve of serum IGFBP4 expression to assist in CC diagnosis was 0.9206 (cut‐off, 0.8450; sensitivity, 86.30%; specificity, 81.51%). Low serum expression of IGFBP4 augmented the risk of poor prognosis in CC patients and was an independent risk factor for poor prognosis. Conclusion Low serum expression of IGFBP4 can assist in CC diagnosis and is an independent risk factor for the dismal prognosis of CC patients.

The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis

This meta-analysis aims to systematically analyze the efficacy and toxicity of mirvetuximab soravtansine (MIRV) as second-line and above treatment for advanced or recurrent ovarian cancer. Candidate studies were identified in PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases up to 1 May 2023. Objective response rate (ORR), progression-free survival (PFS), the incidence of adverse events (AEs), and incidence of grade ≥ 3 AEs were extracted and calculated by meta-analysis of merging ratios or mean to describe the efficacy and toxicity of MIRV. Seven eligible prospective studies were included in this meta-analysis, including 605 patients with advanced ovarian cancer who received second-line or higher therapy. ORR of MIRV was 34.2% (95% confidence interval [CI] 25.0-43.5), and PFS was 5.82 months (95%CI 4.47-7.18). The overall incidence of AEs was 87.4% (95%CI 52.9-100.0) and the incidence of grade ≥ 3 AEs was 27.1% (95%CI 18.9-36.1). The most common AEs were vision blurring, nausea, and diarrhea, with incidence of 46.7% (39.6-53.8), 41.8% (34.0-49.9), and 41.3% (30.4-52.5), respectively. MIRV has definite efficacy and good safety as a novel choice for second-line and above treatment of advanced or recurrent FRα positive ovarian cancer. This may have promising application in patients with platinum-resistant diseases. CRD42023428599.